Vertex Pharmaceuticals (NASDAQ:VRTX) is a global biotechnology company focused on discovering, developing and commercializing transformative medicines for people with serious diseases. Since its founding in 1989, Vertex has been committed to addressing the underlying causes of disease through scientific innovation, with an initial focus on cystic fibrosis and an expanding pipeline targeting genetic disorders, pain and other intractable conditions.
The company’s portfolio is led by its cystic fibrosis therapies, including small-molecule modulators that improve lung function by correcting protein defects in patients with specific genetic mutations. Key products that have shaped the standard of care in cystic fibrosis include Kalydeco, Orkambi, Symdeko (Symkevi in certain markets) and Trikafta (known as Kaftrio in Europe), each approved in multiple countries. Beyond CF, Vertex is advancing investigational programs in gene editing—most notably in partnership with CRISPR Therapeutics—to develop potential one-time treatments for sickle cell disease and beta-thalassemia, as well as novel approaches for pain management and rare metabolic disorders.
Headquartered in Boston, Massachusetts, Vertex maintains research and development facilities in Cambridge, U.K., and other sites across North America, Europe and Australasia. The company’s global commercial organization supports patients and healthcare providers in more than 30 countries, leveraging collaborations with local partners to expand access and deliver value-based care. Vertex also invests in external alliances and academic collaborations to accelerate the translation of cutting-edge science into new therapeutic candidates.
Reshma Kewalramani, M.D., has served as Vertex’s Chief Executive Officer since 2020, leading the company’s strategic vision and commitment to patient impact. Under her leadership, Vertex continues to build a deep pipeline of next-generation therapies, invest in advanced research platforms and uphold a patient-centric culture. The executive team combines expertise in drug discovery, regulatory affairs and commercial operations to drive sustainable growth and scientific excellence.
